Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
World Journal of Urology
Erschienen in: World Journal of Urology 6/2005

01.12.2005 | Topic Paper

Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction

verfasst von: Alberto Briganti, Andrea Salonia, Federico Deho’, Giuseppe Zanni, Luigi Barbieri, Patrizio Rigatti, Francesco Montorsi

Erschienen in: World Journal of Urology | Ausgabe 6/2005

Einloggen, um Zugang zu erhalten

Abstract

Erectile dysfunction (ED) affects the sexual lives of millions of men. The first-line oral pharmacotherapy for most ED patients is phosphodiesterase type-5 (PDE-5) inhibitors, of which three are available. Sildenafil is the most widely prescribed oral agent for ED and has a very satisfactory efficacy–safety profile in all patient categories. Tadalafil and vardenafil were introduced in the European Union and in the United States in 2003 and 2004, respectively. The three PDE-5 inhibitors share many pharmacological and clinical characteristics, and each has unique features. This review, which is based on the contemporary literature on PDE-5 inhibitors, describes the chemical, pharmacological, and clinical features of sildenafil, vardenafil, and tadalafil. The first section reviews the pathophysiology of penile erection and PDE-5 inhibitor pharmacology. The second section summarizes data regarding efficacy and safety of the three drugs in treating ED in the general population as well as in selected patient categories.
Literatur
1.
Sáenz de Tejada I (2002) Molecular mechanisms for the regulation of penile smooth muscle contractility. Int J Impot Res 14(Suppl. 1):S6–S10CrossRefPubMed
2.
Kim N, Vardi Y, Padma-Nathan H, Daley J, Goldstein I, Sáenz de Tejada I (1993) Oxygen tension regulates the nitric oxide pathway: physiological role in penile erection. J Clin Invest 91:437–442PubMed
3.
Ignarro LJ, Bush PA, Buga GM, Wood KS, Fukuto GM, Rajfer J (1990) Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem Biophys Res Commun 170:839–843CrossRef
4.
Kim N, Azadzoi KM, Goldstein I, Sáenz de Tejada I (1991) A nitric-oxide like factor mediates nonadrenergic noncholinergic neurogenic relaxation of penile corpus cavernosum smooth muscle. J Clin Invest 88:112–118PubMed
5.
Simonsen U, Prieto D, Sáenz de Tejada I, Garcia-Sacristian A (1995) Involvement of nitric oxide in the non-adrenergic non-cholinergic neurotransmission of horse deep penile arteries: role of charybdotoxin-sensitive K(+)-channels. Br J Pharmacol 116:2582–2590PubMed
6.
Holmquist F, Stief CG, Jonas U, Andersson KE (1991) Effects of nitric oxide synthase inhibitor Ng-nitro-L-arginine on the erectile response to cavernous nerve stimulation in the rabbit. Acta Physiol Scand 143:299–304PubMedCrossRef
7.
Kuthe A, Magert H, Ückert S, Forssman WG, Stief CG, Jonas U (2000) Gene expression of the phosphodiesterases 3A and 5A in human corpus cavernosum penis. Eur Urol 38:108–114CrossRefPubMed
8.
Ückert S, Kuthe A, Stief CG, Jonas U (2001) Phosphodiesterase isoenzymes as pharmacological targets in the treatment of male erectile dysfunction. World J Urol 19:14–22PubMedCrossRef
9.
Andersson KE (2001) Pharmacology of erectile function and dysfunction. Urol Clin North Am 28:233–247CrossRefPubMed
10.
Andersson KE, Hedlund P (2002) New directions for erectile dysfunction therapies. Int J Impot Res 14(Suppl. 1):S82–S92CrossRefPubMed
11.
Lin CS, Lau A, Tu R, Lue TF (2000) Expression of three isoforms of cGMP binding cGMP-specific phosphodiesterase (PDE5) in human penile cavernosum. Biochem Biophys Res Commun 268:628–635CrossRefPubMed
12.
Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA (1998) Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 338:1397–1404PubMedCrossRef
13.
U.S. Food and Drug Administration submission (1997) Viagra labelling information. Pfizer, New York
14.
Warrington JS, Shader RI, von Moltke LL, Greenblatt DJ (2000) In vitro biotransformation of sildenafil (Viagra): identification of human cytochromes and potential drug interactions. Drug Metab Dispos 28:392–397PubMed
15.
Montorsi F, McDermott T, Morgan R, Olsson A, Schultz A, Kirkeby HJ, Osterloh IH (1999) Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies. Urology 53:1011–1018CrossRefPubMed
16.
Krenzelok EP (2000) Sildenafil: clinical toxicology profile. J Toxicol Clin Toxicol 38:645–651CrossRefPubMed
17.
Milligan PA, Marshall SF, Karlsson MO (2002) A population pharmacokinetic analysis of sildenafil citrate in patients with erectile dysfunction. Br J Clin Pharmacol 53:S45–S52CrossRef
18.
Sáenz de Tejada I, Angulo J, Cuevas P, Fernandez A, Moncada I, Allona A, Lledo E, Korschen HG, Niewohner U, Haning H, Pages E, Bischoff E (2001) The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int J Impot Res 13:282–290CrossRefPubMed
19.
Gbekor E, Bethell S, Fawcett L, Mount N, Phillips S (2002) Selectivity of sildenafil and other phosphodiesterase type 5 (PDE5) inhibitors against all human phosphodiesterase families. Eur Urol 1(Suppl. 1):63
20.
Kim NN, Huang YH, Goldstein I, Bischoff E, Trais AM (2001) Inhibition of cyclic GMP hydrolysis in human corpus cavernosum smooth muscle cells by vardenafil, a novel, selective phosphodiesterase type 5 inhibitor. Life Sci 69:2249–2256CrossRefPubMed
21.
Stark S, Sachse R, Liedl T, Hensen J, Rohde G, Wensing G, Horstmann R, Schrott KM (2001) Vardenafil increases penile rigidity and tumescence in men with erectile dysfunction after a single oral dose. Eur Urol 40:181–188CrossRefPubMed
22.
Rajagopalan P, Mazzu A, Xia C, Dawkins R, Sundaresan P (2003) Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction. J Clin Pharmacol 43:260–267CrossRefPubMed
23.
Klotz T, Bauer RJ, Rohde G (2002) Effect of renal impairment on the single-dose pharmacokinetics of vardenafil 20 mg, a selective PDE5 inhibitor for the treatment of erectile dysfunction. Pharmacotherapy 22:418
24.
Patterson B, Bedding A, Jewell H, Payne C, Mitchell M (2001) Dose normalized pharmacokinetics of tadalafil (IC351) in healthy volunteers. Int J Impot Res 13(Suppl. 5):S62–A14
25.
Cialis summary of product characteristics, EMEA (2003), Lilly ICOS Limited, November
26.
Fawcett L, Baxendale R, Stacey P, McGrouther C, Harrow I, Soderling S, et al (2000) Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. Proc Natl Acad Sci USA 97:3702CrossRefPubMed
27.
Patterson B, Bedding A, Jewell H, Mitchell M (2001) The effect of intrinsic and extrinsic factors on the pharmacokinetic properties of tadalafil (IC351). Int J Impot Res 13(Suppl. 5):S43
28.
Porst H, Padma-Nathan H, Giuliano F, Anglin G, Varanese L, Rosen R (2003) Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. Urology 62:121–125CrossRefPubMed
29.
Cialis® (tadalafil) package insert, Food and Drug Administration (2003), Lilly ICOS LLC
30.
Ashton AK, Bennett RG (1991) Sildenafil treatment of serotonin reuptake inhibitor-induced sexual dysfunction. J Clin Psychiatry 60:194–195CrossRef
31.
Nurnberg HG, Lauriello J, Hensley PL, Parker LM, Keith SJ (1999) Sildenafil for iatrogenic serotoninergic antidepressant medication-induced sexual dysfunction in 4 patients. J Clin Psychiatry 60:33–35PubMedCrossRef
32.
Rosenberg KP (1999) Sildenafil citrate for SSRI-induced sexual side effects. Am J Psychiatry 156:157PubMed
33.
Meuleman E, Cuzin B, Opsomer RJ, Hartmann U, Bailey MJ, Maytom MC, Smith MD, Osterloh IH (2001) A dose-escalation study to assess the efficacy and safety of sildenafil citrate in men with erectile dysfunction. BJU Int 87:75–81CrossRefPubMed
34.
Boulton AJM, Selam JL, Sweeney M, Ziegler D (2001) Sildenafil citrate for the treatment of erectile dysfunction in men with Type II diabetes mellitus. Diabetologia 44:1296–1301CrossRefPubMed
35.
Carson CC, Burnett AL, Levine LA, Nehra A (2002) The efficacy of sildenafil citrate (Viagra) in clinical populations: an update. Urology 60(Suppl. 2):12–27CrossRefPubMed
36.
Moore RA, Edwards JE, McQuay HJ (2002) Sildenafil (Viagra™) for male erectile dysfunction: a meta-analysis of clinical trial reports. BMC Urol 2:6CrossRefPubMed
37.
Fink HA, MacDonald R, Rutks IR, Nelson DB, Wilt TJ (2002) Sildenafil for male erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med 162:1349–1360CrossRefPubMed
38.
Lewis R, Bennet CJ, Borkon WD, Boykin WH, Althoff SE, Stecher VJ, Siegel RL (2001) Patient and partner satisfaction with Viagra (sildenafil citrate) treatment as determined by the Erectile Dysfunction Inventory of Treatment Satisfaction Questionnaire. Urology 57:960–965CrossRefPubMed
39.
Althof SE, Corty EW, Levine SB (1999) EDITS: development of questionnaires for evaluating satisfaction with treatments for erectile dysfunction. Urology 53:793–799CrossRefPubMed
40.
Padma-Nathan H, Eardley I, Kloner RA, Laties AM, Montorsi F (2002) A 4-year update on the safety of sildenafil citrate (Viagra). Urology 60(2 Suppl 2):67–90CrossRefPubMed
41.
Padma-Nathan E, McCullough AR, Giuliano F, Toler SM,Wohlhuter C, Shpilsky AB (2003) Postoperative nightly administration of sildenafil citrate significantly improves the return of normal spontaneous erectile function after bilateral nerve-sparing radical prostatectomy. J Urol 4(Suppl):375
42.
Behr-Roussel D, Gorny D, Mevel K, Caisey S, Bernabè J, Burgess G, Wayman C, Alexandre L, Giuliano F (2005) Chronic sildenafil improves erectile function and endothelium-dependent cavernosal relaxations in rats: lack of tachyphylaxis. Eur Urol 47:87–91CrossRefPubMed
43.
Rendell MS, Rajfer J, Wicker PA, Smith MD (1999) Sildenafil for the treatment of erectile dysfunction in men with diabetes. JAMA 281:421–426CrossRefPubMed
44.
Hirsch IB, Korenman SG, Stecher V, Diuguid C (1999) Viagra® (sildenafil citrate): efficacy and safety in the treatment of erectile dysfunction (ED) in men with diabetes. In: American Diabetes Association Meeting, 19–22 June, San Diego
45.
Stuckey B, Jadzinsky MN, Murphy LJ, Montorsi F, Kadioglu A, Fraige F, Manzano P, Deerochanawong C (2003) Sildenafil citrate for treatment of erectile dysfunction in men with type 1 diabetes mellitus. Results of a randomised controlled trial. Diabetes Care 26:279–284PubMedCrossRef
46.
Boulton AJM, Selam JL, Sweeney M, Ziegler D (2001) Sildenafil citrate for the treatment of erectile dysfunction in men with Type II diabetes mellitus. Diabetologia 44:1296–1301CrossRefPubMed
47.
Halcox JP, Nour KR, Zalos G, Mincemoyer RA, Waclawiw M, Rivera CE, Willie G, Ellahham S, Quyyumi AA (2002) The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J Am Coll Cardiol 40:1232–1240CrossRefPubMed
48.
Arruda-Olson AM, Mahoney DW, Nehra A, Leckel M, Pellikka PA (2002) Cardiovascular effects of sildenafil during exercise in men with known or probable CAD. JAMA 287:719–725CrossRefPubMed
49.
Katz SD, Balidemaj K, Homma S, Wu H, Wang J, Maybaum S (2000) Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol 36:845–851CrossRefPubMed
50.
Hellstrom WJG, Gittelman M, Karlin G, Segerson T, Thibonnier M, Taylor T, Padma-Nathan H, on behalf of the Vardenafil Study Group (2002) Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 23:763–771
51.
Goldstein I, Young JM, Fischer J, Bangerter K, Segerson T, Taylor T (2003) Vardenafil, a new phosphodiesterase type 5 inhibitor in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 26:777–783PubMedCrossRef
52.
Porst H, Rosen R, Padma-Nathan H, Goldstein I, Giuliano F, Ulbrich E, Bandel T (2001) The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res 13:192–199CrossRefPubMed
53.
Stief C, Porst H, de Tejada S, Ulbrich E, Beneke M (2004) Sustained efficacy and tolerability with vardenafil over 2 years of treatment in men with erectile dysfunction. Int J Clin Pract 58:230–239CrossRefPubMed
54.
Brock G, Nehra A, Lipshultz LI, Karlin GS, Gleave M, Seger M, Padma-Nathan H (2003) Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy. J Urol 170:1278–1283CrossRefPubMed
55.
Potempa A-J, Ulbrich E, Bernard I, Beneke M, on behalf of the Vardenafil Study Group (2004) Efficacy of vardenafil in men with erectile dysfunction: a flexible dose community practice study. Eur Urol 46:73–79
56.
Hatzichristou D, Montorsi F, Buvat J, Laferriere N, Bandel T, Porst H (2004) The efficacy and safety of flexible-dose vardenafil (Levitra) in a broad population of European men. Eur Urol 45:634–641CrossRefPubMed
57.
Giuliano F, Donatucci C, Montorsi F, Auerbach S, Karlin G, Norenberg C, Homering M, Segerson T, Eardley I, Vardenafil Study Group (2005) Vardenafil is effective and well tolerated for treating erectile dysfunction in a broad population of men, irrespective of age. BJU Int 95:110–116
58.
Valiquette L, Montorsi F, Hellstrom WJ, Giuliano F, Homering M, Taylor T, Eardley I, Vardenafil Study Group (2005) Penetration and maintainence of erection with vardenafil: a time-from-dosing analysis. Can J Urol 12:2687–2698
59.
Hellstrom WJ, Elhilali M, Homering M, Taylor T, Gittleman M (200) Vardenafil in patients with erectile dysfunction: achieving treatment optimization. J Androl 26:604–609
60.
Montorsi F, Hellstrom WJ, Valiquette L, Bastuba M, Collins O, Taylor T, Thibonnier, Homering M, Eardley I (2004) North American and European Vardenafil Groups. Vardenafil provides reliable efficacy over time in men with erectile dysfunction. Urology 64:1187–1195CrossRefPubMed
61.
Hellstrom WJ, Gittelman M, Karlin G, Segerson T, Thibonnier M, Taylor T, Padma-Nathan H on behalf of Vardenafil Study Group (2003) Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. Urology 61(4 Suppl. 1):8–14
62.
Nehera A, Grantmyre J, Nadel A, Thibonnier M, Brock G (2005) Vardenafil improved patient satisfaction with erectile hardness, orgasmic function and sexual experience in men with erectile dysfunction following nerve sparing radical prostatectomy. J Urol 173:2067–2071CrossRefPubMed
63.
Thadani U, Smith W, Nash S, Bittar N, Glasser S, Narayan P, Stein RA, Larkin S, Mazzu A, Tota R, Pomerantz K, Sundaresan P (2002) The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol 40:2006–2012CrossRefPubMed
64.
Padma-Nathan H, Rosen RC, Shabsigh R et al (2001) Cialis (IC351) provides prompt response and extended period of responsiveness in the treatment of men with erectile dysfunction (ED). J Urol 165(Suppl):A923
65.
Padma-Nathan H, McMurray JG, Pullman WE et al (2001) On demand IC351 (Cialis) enhances erectile function in patients with erectile dysfunction. Int J Impot Res 13:2–9CrossRefPubMed
66.
Brock GB, McMahon CG, Chen KK, Costigan T, Shen W, Watkins V et al (2002) Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 168:1332CrossRefPubMed
67.
Mirone V, van Ahlen H. for the SURE Study Investigators (2005) Efficacy and safety of tadalafil scheduled vs. on demand in men with erectile dysfunction: The SURE Study. Eur Urol 47:846–854
68.
Rosano G, Aversa A, Vitale C, Fabbri A, Fini M, Spera G (2005) Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol 47:214–222CrossRefPubMed
69.
Montorsi F, Verheyden B, Meuleman E, Juneman KP, Moncada I, Valiquette L, Casabè A, Pacheco C, Denne J, Knight J, Segal S, Watkins VS (2004) Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction. Eur Urol 45:339–345CrossRefPubMed
70.
Sáenz de Tejada I, Anglin G, Knight JR, Emmick J (2002) Effets of tadalafil on erectile dysfunction in men with dibetes. Diabetes Care 25:2159–2164PubMedCrossRef
71.
Strojek K, Price D, Fonseca V, Fredlund P (2003) Tadalafil improves erectile function in men with erectile dysfunction and diabetes mellitus. Int J Impot Res 15(Suppl 6):S26CrossRef
72.
Montorsi F, McCullough A, Brock GB et al (2004) Tadalafil in the treatment of erectile dysfunction following bilateral nerve-sparing radical retropubic prostatectomy: a randomized, double-blind, placebo-controlled trial. J Urol 172:1036–1041CrossRefPubMed
73.
Kloner RA, Mitchell M, Emmick JT (2003) Cardiovascular effects of tadalafil in patients on common antihypertensive therapy. Am J Cardiol 92(Suppl. 1):47–57CrossRefPubMed
74.
Kloner RA, Hutter AM, Emmick JT, et al (2003) Time course of the interaction between tadalafil and nitrates. JACC 42:1885–1860
75.
Hellstrom WJG, Overstreet JW, Yu A et al (2003) Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones. J Urol 170:887–891CrossRefPubMed
Metadaten
Titel
Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction
verfasst von
Alberto Briganti
Andrea Salonia
Federico Deho’
Giuseppe Zanni
Luigi Barbieri
Patrizio Rigatti
Francesco Montorsi
Publikationsdatum
01.12.2005
Verlag
Springer-Verlag
Erschienen in
World Journal of Urology / Ausgabe 6/2005
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-005-0022-6

Weitere Artikel der Ausgabe 6/2005

World Journal of Urology 6/2005 Zur Ausgabe

Topic Paper

Distribution and functional significance of phosphodiesterase isoenzymes in the human lower urinary tract

Topic Paper

Nitric oxide/cGMP-mediated effects in the outflow region of the lower urinary tract—is there a basis for pharmacological targeting of cGMP?

Invited editorial

Editorial

Topic Paper

Phosphodiesterase inhibitors in female sexual dysfunction

Original Article

Follow-up of men obtaining a six-core versus a ten-core benign prostate biopsy 7 years previously

Topic Paper

Treating erectile dysfunction by endothelial rehabilitation with phosphodiesterase 5 inhibitors

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

Stufenschema weist Prostatakarzinom zuverlässig nach

22.04.2024 Prostatakarzinom Nachrichten

Erst PSA-Test, dann Kallikrein-Score, schließlich MRT und Biopsie – ein vierstufiges Screening-Schema kann die Zahl der unnötigen Prostatabiopsien erheblich reduzieren: Die Hälfte der Männer, die in einer finnischen Studie eine Biopsie benötigten, hatte einen hochgradigen Tumor.

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

20.04.2024 EAU 2024 Kongressbericht

Beim chronischen Harnwegsinfekt bei Frauen wird bisher meist eine Antibiotikaprophylaxe eingesetzt. Angesichts der zunehmenden Antibiotikaresistenz erweist sich das Antiseptikum Methenamin-Hippurat als vielversprechende Alternative, so die Auswertung einer randomisierten kontrollierten Studie.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise